The digitization of health is very much a work in progress, but there are now many and varied initial deployments that give a sense of the benefits that will flow from the comprehensive and integrated application of digital technologies in health care. Read More
Australian scientists have found a new way to make molecular isomers, opening up the possibility of a new area of chemistry and the development of countless new drugs and other useful new materials. Read More
HONG KONG – Israeli biotech firm Atox Bio Inc., of Ness Ziona, is moving ahead with its lead product, reltecimod (AB-103), with two clinical trials ongoing in parallel in the U.S. The funds from the financing round last December will help speed up the development of the drug candidate, pushing it closer to approval in two year's time. Read More
HONG KONG – South Korea is striving to be a global hub for biosimilars, as domestic biopharma firms such as Celltrion Inc., Samsung Bioepis Co. Ltd. and LG Chem Ltd. are all spearheading their biosimilars development. Read More
BEIJING – Freshly installed Commissioner Jiao Hong of the China National Drug Administration, formerly the CFDA, voiced the agency's plans to streamline review and approval of new drugs, encourage innovation, improve capacity to take a science-based approach, deepen industry's quality control efforts and step up monitoring of adverse events. Read More
The technologies underlying the switch to digital health are here and now, but alongside technical complexities of connecting silos of information spread around medical specialties and perfecting the interoperability of IT systems, a number of issues stand in the way of applying digital health at scale. Read More
HONG KONG – China's Luye Pharma Group Ltd. has partnered up with U.S. biotech firm Elpis Biopharmaceuticals Corp. to work on dual target-based therapies for cancer patients who fail to respond to current treatment. Read More
Mesoblast Ltd., of Melbourne, Australia, appointed Josh Muntner chief financial officer, based in New York. Muntner has 20 years of experience in healthcare investment banking and corporate finance. Read More
Lion TCR Pte. Ltd., of Singapore, said it raised $20 million in a series A financing round. The proceeds will be primarily used to advance its ongoing clinical trials of lead candidate Liocyx (personalized HBV specific TCR T-cell therapy against HCC) in major hospitals in China and Singapore, as well as for broadening its products pipeline to fight viral-related solid tumors and clearance of chronic hepatitis B. Read More
